ZSAN
Income statement / Annual
Last year (2021), Zosano Pharma Corporation's total revenue was $785.00 K,
an increase of 250.45% from the previous year.
In 2021, Zosano Pharma Corporation's net income was -$30.11 M.
See Zosano Pharma Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$785.00 K |
$224.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$313.00 K |
$2.86 M |
$4.25 M |
$11.62 M |
| Cost of Revenue |
$796.00 K
|
$171.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$100.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
-$11.00 K
|
$53.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$313.00 K
|
$2.76 M
|
$4.25 M
|
$11.62 M
|
| Gross Profit Ratio |
-0.01
|
0.24
|
0
|
0
|
0
|
0
|
1
|
0.97
|
1
|
1
|
| Research and Development Expenses |
$20.97 M
|
$21.62 M
|
$25.39 M
|
$25.51 M
|
$20.19 M
|
$20.46 M
|
$20.37 M
|
$10.95 M
|
$7.64 M
|
$5.40 M
|
| General & Administrative Expenses |
$10.55 M
|
$11.19 M
|
$11.81 M
|
$9.36 M
|
$8.18 M
|
$8.18 M
|
$6.32 M
|
$4.42 M
|
$4.58 M
|
$3.08 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.55 M
|
$11.19 M
|
$11.81 M
|
$9.36 M
|
$8.18 M
|
$8.18 M
|
$6.32 M
|
$4.42 M
|
$4.58 M
|
$3.08 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$31.52 M
|
$32.81 M
|
$37.20 M
|
$34.87 M
|
$28.37 M
|
$28.63 M
|
$26.68 M
|
$15.37 M
|
$12.22 M
|
$8.48 M
|
| Cost And Expenses |
$32.32 M
|
$32.98 M
|
$37.20 M
|
$34.87 M
|
$28.37 M
|
$28.63 M
|
$26.68 M
|
$15.47 M
|
$12.22 M
|
$8.48 M
|
| Interest Income |
$3.00 K
|
$18.00 K
|
$207.00 K
|
$381.00 K
|
$0.00
|
$0.00
|
$235.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$189.00 K
|
$719.00 K
|
$523.00 K
|
$379.00 K
|
$742.00 K
|
$0.00
|
$1.80 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.75 M
|
$1.43 M
|
$683.00 K
|
$764.00 K
|
$2.55 M
|
$2.54 M
|
$2.45 M
|
$3.04 M
|
$428.00 K
|
$1.07 M
|
| EBITDA |
-$27.99 M |
-$31.22 M |
-$36.38 M |
-$34.22 M |
-$25.81 M |
-$27.29 M |
-$24.18 M |
-$11.20 M |
-$5.18 M |
$2.89 M |
| EBITDA Ratio |
-35.65
|
-139.39
|
0
|
0
|
0
|
0
|
-77.24
|
-3.91
|
-1.22
|
0.25
|
| Operating Income Ratio |
-37.88
|
-146.24
|
0
|
0
|
0
|
0
|
-84.24
|
-4.41
|
-1.88
|
0.27
|
| Total Other Income/Expenses Net |
-$189.00 K
|
-$611.00 K
|
-$392.00 K
|
$18.00 K
|
-$735.00 K
|
-$1.20 M
|
-$2.06 M
|
-$1.63 M
|
$2.36 M
|
-$1.33 M
|
| Income Before Tax |
-$29.93 M
|
-$33.37 M
|
-$37.59 M
|
-$35.36 M
|
-$29.11 M
|
-$29.83 M
|
-$28.43 M
|
-$14.24 M
|
-$5.61 M
|
$1.82 M
|
| Income Before Tax Ratio |
-38.12
|
-148.97
|
0
|
0
|
0
|
0
|
-90.82
|
-4.98
|
-1.32
|
0.16
|
| Income Tax Expense |
$189.00 K
|
$0.00
|
$0.00
|
$0.00
|
$7.00 K
|
$0.00
|
-$260.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$30.11 M
|
-$33.37 M
|
-$37.59 M
|
-$35.36 M
|
-$29.11 M
|
-$29.83 M
|
-$28.43 M
|
-$14.24 M
|
-$5.61 M
|
$1.82 M
|
| Net Income Ratio |
-38.36
|
-148.97
|
0
|
0
|
0
|
0
|
-90.82
|
-4.98
|
-1.32
|
0.16
|
| EPS |
-0.27 |
-0.49 |
-2.29 |
-3.74 |
-16.82 |
-43.32 |
-49.81 |
-24.52 |
-21.52 |
6.98 |
| EPS Diluted |
-0.27 |
-0.49 |
-2.29 |
-3.74 |
-16.82 |
-43.32 |
-49.81 |
-24.52 |
-21.52 |
6.98 |
| Weighted Average Shares Out |
$112.06 M
|
$67.91 M
|
$16.38 M
|
$9.45 M
|
$1.73 M
|
$688.65 K
|
$570.70 K
|
$580.81 K
|
$260.55 K
|
$260.55 K
|
| Weighted Average Shares Out Diluted |
$112.06 M
|
$67.91 M
|
$16.38 M
|
$9.45 M
|
$1.73 M
|
$688.65 K
|
$570.70 K
|
$580.81 K
|
$260.55 K
|
$260.55 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
